< 首頁 - 合作夥伴 - 臨床試驗受託機構 - 艾默生物醫學股份有限公司
臨床試驗受託機構

艾默生物醫學股份有限公司 EMO Biomedicine Corp.

卓越成果

2000-2016

Disease Area/ Indication

Name of PI

Name of Trial

phase I-III

Name of sponsor

Remarks

Chronic Hepatitis B

高嘉宏

郭行道

A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region

IIB-III

ABIVAX SA

Multi- national

Ischemic Limb Disease

洪士杰

Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

I

台宝生醫股份有限公司

Taiwan Bio Therapeutics Co., Ltd.

 

HIV-1 infected

王永衛

蔡宏津

A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults

I

聯亞生技開發股份有限公司

United Biomedical, Inc., Asia (UBI Asia)

 

Preservation for Germ line stem cells

周永強

Cryogenic Preservation and Subsequent Transplantation of Germ Line Stem Cells in Male Pre-pubescent Patients

I

馬偕紀念醫院

MacKay Memorial Hospital

 

專長服務項目

  • Contract Manufacturing Services for Cell Product EMO offers GTP/GMP compliant facility and Quality Management System (QMS) for cell product manufacturing
  • Contract Analysis/Testing Services A. Testing service for clinical samples, including protein quantification and flowcytometry-related testing. B. Safety test and potency assay for cell product, including endotoxin testing, mycoplasma testing, sterility, cell surface marker analysis and etc.
  • Contract Research Services EMO offers customized services for preclinical study.

提供實驗室服務

國際認證

財團法人醫藥品查驗中心 T : 請至聯絡我們留言